Royalty Pharma Commits $7.5M to Blood Cancer United’s Therapy Acceleration Program
Event summary
- Royalty Pharma pledged $7.5 million to Blood Cancer United’s Therapy Acceleration Program (TAP) to accelerate blood cancer therapy development.
- The donation marks a new phase for TAP, with Royalty Pharma as the first and largest corporate donor under an updated model inviting direct donations.
- TAP deploys donations as venture capital investments in early-stage biotech companies, providing funding, expertise, and strategic guidance.
- Financial returns from TAP are reinvested into the program to support future partnerships and investments.
- Blood Cancer United committed an additional $15 million to support TAP’s continued growth.
The big picture
Royalty Pharma’s $7.5 million donation to Blood Cancer United’s Therapy Acceleration Program underscores a strategic shift towards venture philanthropy in biotech. This move aligns with broader industry trends of corporate funding for early-stage biotech companies, aiming to bridge the gap between scientific discovery and patient access. The reinvestment model aims to create a sustainable cycle of funding and innovation, potentially setting a new standard for collaborative efforts in blood cancer research.
What we're watching
- Impact of Reinvestment
- Whether the reinvestment model can sustain long-term growth and accelerate therapy development.
- Therapy Development Pace
- The pace at which TAP-supported therapies advance through clinical trials and regulatory approvals.
- Industry Collaboration
- How Royalty Pharma’s involvement will influence future partnerships and investments in blood cancer research.
Related topics